Cerebrolysin (60mg Vial) Dosage Protocol
Porcine-brain-derived neuropeptide mixture — approved abroad for stroke/dementia/TBI, not FDA-approved in the US.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Cerebrolysin · 60 mg
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = 20 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 60 mg vial → final concentration 20 mg/mL. (Applies to a research-grade lyophilized powder only.)
Typical daily range: 20 mg/day (Week 1), titrated to 24, 28 then 32 mg/day; from Week 2 onward the daily amount is split into AM and PM injections.
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg on a U-100 syringe, so units = mg ÷ 0.2 (e.g. 20 mg = 100 units, 32 mg = 160 units).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Why Cerebrolysin draws research interest
These are the directions researchers and the peptide community most often explore Cerebrolysin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Cognition / nootropic
Explored in research on memory, focus and learning, drawing on its neuropeptide and neurotrophic-factor content.
Neuroprotection
Studied for how its peptide fractions may support neuronal survival and repair signaling in preclinical models.
Stroke & TBI recovery
Investigated in trials on ischemic stroke and traumatic brain injury; approved for these abroad but not FDA-approved in the US.
Dementia research
Researched as an investigational agent in Alzheimer's and vascular dementia studies, where it is used clinically in some countries only.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Cerebrolysin is a porcine (pig) brain-derived mixture of low-molecular-weight neuropeptides and free amino acids, hypothesized to mimic neurotrophic factors such as BDNF, NGF and GDNF[1][5]. It is marketed in 50+ countries for stroke, dementia and TBI, but is not FDA-approved in the United States and the human evidence is mixed and inconclusive. This page reproduces a research-powder reconstitution scheme for educational reference only. Note: commercial Cerebrolysin is actually a ready-to-use liquid given by clinicians intramuscularly or intravenously — never subcutaneously — so the powder/SC protocol below is not standard medical practice.
Add 3.0 mL bacteriostatic water to one 60 mg vial → 20 mg/mL. Research-powder scheme only; real Cerebrolysin is a ready-to-use liquid.
20 mg/day in Week 1, titrated up to 32 mg/day by Week 4+, with later doses split into AM and PM injections.
At 20 mg/mL, 1 unit = 0.2 mg on a U-100 syringe; so 20 mg = 100 units and 32 mg = 160 units (units = mg ÷ 0.2).
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: Week 1 is a single daily dose; from Week 2 the daily amount is split into a morning and an evening injection as the total rises[3][4]. This subcutaneous, powder-based scheme is an educational reconstruction only and does not reflect how clinical Cerebrolysin is actually given.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Reality check: real commercial Cerebrolysin is a ready-to-use liquid concentrate (215.2 mg/mL) supplied in glass ampoules and given intramuscularly or intravenously by clinicians — never subcutaneously, with no reconstitution. The lyophilized-powder, subcutaneous protocol described here applies only to a research-grade powder and is educational, not standard medical practice. Avoid freezing the reconstituted solution.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with gradual titration.
Quantities depend on the daily dose; one 60 mg vial covers roughly 2–3 days at 20–32 mg/day.
- 8 weeks: ~27 vials
- 12 weeks: ~42 vials
- 16 weeks: ~57 vials
- Per injection: 1 syringe
- 8 weeks (AM+PM from Wk 4): ~95 syringes
- 16 weeks (AM+PM from Wk 4): ~200 syringes
Use ~3.0 mL per 60 mg vial for reconstitution.
- 8 weeks (8 vials): ~24 mL → 3 bottles
- 16 weeks (16 vials): ~48 mL → 5 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.
- ▪Goal: Cerebrolysin is hypothesized to provide neurotrophic support relevant to stroke, dementia and TBI — effects largely inferred from preclinical work and not proven in humans; a 2022 Cochrane review found insufficient evidence in acute ischemic stroke[5][6].
- ▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
- ▪Dose Range: 20 mg/day in Week 1, titrated to 24, 28 then 32 mg/day, with the daily total split AM/PM from Week 2 onward.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 60 mg vial gives 20 mg/mL (research-powder scheme only; clinical Cerebrolysin is a ready-to-use liquid).
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A suggested daily titration approach based on common reference doses.
- ▪Start: Begin at 20 mg once daily (Week 1) to gauge tolerability.
- ▪Titrate: Increase by about 4 mg each week (24, 28, then 32 mg/day) as tolerated, splitting the dose AM/PM from Week 2.
- ▪Target: Reach about 32 mg daily by Week 4 and hold there.
- ▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Cerebrolysin is not FDA-approved in the US (no NDA), though it is marketed in 50+ countries abroad; it is also a porcine-derived biological product carrying the usual biologic-sourcing considerations[10].
How This Works
Cerebrolysin is a porcine (pig) brain-derived mixture of low-molecular-weight neuropeptides and free amino acids, produced by enzymatic breakdown of pig brain tissue[1][2]. It is not a single defined molecule but a complex biological mixture.
Its proposed mechanism is to mimic endogenous neurotrophic factors such as BDNF, NGF and GDNF, potentially supporting neuronal survival, plasticity and repair[5][6]. This mechanism is largely inferred from preclinical work and has not been proven in humans.
Cerebrolysin is approved and marketed in 50+ countries across Europe, Russia, Asia and Latin America for stroke, dementia and traumatic brain injury[11], but the clinical evidence is mixed and inconclusive — a 2022 Cochrane review found insufficient evidence to support its use in acute ischemic stroke[12].
Important caveat: Cerebrolysin is not FDA-approved in the United States (no NDA on file). Cognitive and neuroprotective benefits should not be overstated — the strongest claims rest on heterogeneous trials and preclinical models, and high-quality evidence remains limited.
Cerebrolysin is not approved in the United States. This page is presented for educational and informational purposes only and is not medical advice.
Lifestyle Factors
Habits that may support recovery alongside the protocol.
- ▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
- ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What the international clinical and preclinical literature describes; the human evidence base is mixed and inconclusive, and individual results vary.
Potential Benefits
- ▪Neurotrophic support (preclinical): Cerebrolysin is hypothesized to mimic BDNF/NGF/GDNF activity and has shown neuroprotective signals in animal models[5][6].
- ▪Approved use abroad: Used clinically in 50+ countries for stroke, dementia and TBI, though trial results are heterogeneous[11].
- ▪Tolerability: Generally reported as well tolerated in clinical use abroad, with mostly mild adverse effects.
- ▪Evidence caveat: Benefits are not firmly established — a 2022 Cochrane review found insufficient evidence in acute ischemic stroke, and it is not FDA-approved in the US[13].
Common Side Effects
- ▪Common effects: Dizziness, headache, sweating, mild agitation or injection-site reactions have been reported.
- ▪US status: Not FDA-approved in the US, so it is not subject to US manufacturing oversight; sourcing and quality vary.
- ▪Porcine source: It is a pig-brain-derived biological mixture, which carries the usual biologic-sourcing and allergy considerations.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
Cerebrolysin is a porcine-derived biological mixture and is generally not sold as a research peptide. For high-purity research peptides and supplies more broadly, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Journal of Neural TransmissionComposition and neurotrophic hypothesis of Cerebrolysin: a porcine-brain-derived mixture of neuropeptides and amino acids.
- 2
CNS & Neurological Disorders (PubMed)Pharmacological characterization of Cerebrolysin and its proposed BDNF/NGF/GDNF-like neurotrophic actions.
- 3
U.S. FDA — Drug ApprovalsRegulatory status overview: Cerebrolysin is not FDA-approved in the United States (no NDA on file).
- 4
EVER Neuro Pharma (Manufacturer)International approvals: Cerebrolysin is marketed in 50+ countries for stroke, dementia and TBI.
- 5
Stroke (AHA Journal, PubMed)Preclinical evidence for neuroprotective and neurotrophic effects of Cerebrolysin in animal models.
- 6
Frontiers in Neuroscience (PubMed)Cerebrolysin neurotrophic activity: experimental support for neuronal survival and plasticity.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
Neuropsychiatric Disease & Treatment (PubMed)Cerebrolysin clinical use in traumatic brain injury and dementia: summary of indications abroad.
- 11
Journal of Alzheimer’s DiseaseCerebrolysin in vascular and Alzheimer-type dementia: clinical trial findings (heterogeneous results).
- 12
Cochrane Database of Systematic ReviewsCochrane review (2022): insufficient evidence for Cerebrolysin in acute ischemic stroke.
- 13
ClinicalTrials.govClinicalTrials.gov registry of Cerebrolysin studies across stroke, TBI and dementia indications.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Cerebrolysin Prescribing InformationCerebrolysin product information — ampoule liquid concentrate (215.2 mg/mL) for IM/IV use abroad.
Cerebrolysin — frequently asked questions
How do I reconstitute a 60 mg vial of Cerebrolysin?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Cerebrolysin?
There is no single correct amount — more water simply spreads the same 60 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Cerebrolysin after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 60 mg vial of Cerebrolysin provide?
Divide the vial strength of 60 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Cerebrolysin approved for human use?
No. Cerebrolysin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.